| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Consumption: After 8 hours of sustained loading, only a tiny portion (<23%) of PSB-12379 (10g) was consumed under application conditions. However, >77% of the compound remained unaltered. The 10g of PSB-12379 is a little unstable; after 8 hours, 56% of it was gone. The nuclear sequence is the arrangement of sugar sequence bonds, and the usual I substitution at the top is seen to be the dominant reaction [1].
|
|---|---|
| References |
|
| Molecular Formula |
C18H23N5O9P2
|
|---|---|
| Molecular Weight |
515.3508
|
| Exact Mass |
515.097
|
| CAS # |
1802226-78-3
|
| Related CAS # |
PSB-12379 disodium
|
| PubChem CID |
122207761
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.6
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
785
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
P(C([H])([H])P(=O)(O[H])O[H])(=O)(O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3=C(N=C([H])N=C23)N([H])C([H])([H])C2C([H])=C([H])C([H])=C([H])C=2[H])O1)O[H])O[H]
|
| InChi Key |
DMBYYIJBPDWQFF-SCFUHWHPSA-N
|
| InChi Code |
InChI=1S/C18H23N5O9P2/c24-14-12(7-31-34(29,30)10-33(26,27)28)32-18(15(14)25)23-9-22-13-16(20-8-21-17(13)23)19-6-11-4-2-1-3-5-11/h1-5,8-9,12,14-15,18,24-25H,6-7,10H2,(H,29,30)(H,19,20,21)(H2,26,27,28)/t12-,14-,15-,18-/m1/s1
|
| Chemical Name |
[[(2R,3S,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
|
| Synonyms |
PSB-12379 PSB-12379 disodium N6-Benzyl-α,β-methyleneadenosine 5'-diphosphate disodium salt PSB 12379 PSB12379
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~242.55 mM)
DMSO : ≥ 5 mg/mL (~9.70 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (194.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9404 mL | 9.7021 mL | 19.4043 mL | |
| 5 mM | 0.3881 mL | 1.9404 mL | 3.8809 mL | |
| 10 mM | 0.1940 mL | 0.9702 mL | 1.9404 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
